CN116407636A - Lnc-CCKAR-5在制备抑制MSCs凋亡、提高治疗效果的药物中的应用 - Google Patents
Lnc-CCKAR-5在制备抑制MSCs凋亡、提高治疗效果的药物中的应用 Download PDFInfo
- Publication number
- CN116407636A CN116407636A CN202310541455.3A CN202310541455A CN116407636A CN 116407636 A CN116407636 A CN 116407636A CN 202310541455 A CN202310541455 A CN 202310541455A CN 116407636 A CN116407636 A CN 116407636A
- Authority
- CN
- China
- Prior art keywords
- cckar
- lnc
- expression
- mscs
- inhibiting
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000006907 apoptotic process Effects 0.000 title claims abstract description 48
- 210000004271 bone marrow stromal cell Anatomy 0.000 title claims abstract description 30
- 230000002401 inhibitory effect Effects 0.000 title claims abstract description 30
- 239000003814 drug Substances 0.000 title claims abstract description 21
- 230000000694 effects Effects 0.000 title abstract description 17
- 230000014509 gene expression Effects 0.000 claims abstract description 45
- 206010012601 diabetes mellitus Diseases 0.000 claims abstract description 37
- 230000001737 promoting effect Effects 0.000 claims abstract description 14
- 229940079593 drug Drugs 0.000 claims abstract description 13
- 230000037314 wound repair Effects 0.000 claims abstract description 6
- 206010052428 Wound Diseases 0.000 claims description 39
- 208000027418 Wounds and injury Diseases 0.000 claims description 39
- 108020004459 Small interfering RNA Proteins 0.000 claims description 29
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 26
- 230000000692 anti-sense effect Effects 0.000 claims description 26
- 102000039446 nucleic acids Human genes 0.000 claims description 25
- 108020004707 nucleic acids Proteins 0.000 claims description 25
- 150000007523 nucleic acids Chemical class 0.000 claims description 25
- 239000003795 chemical substances by application Substances 0.000 claims description 24
- 108091027967 Small hairpin RNA Proteins 0.000 claims description 21
- 239000004055 small Interfering RNA Substances 0.000 claims description 21
- 102000040650 (ribonucleotides)n+m Human genes 0.000 claims description 19
- 238000000034 method Methods 0.000 claims description 19
- 239000008194 pharmaceutical composition Substances 0.000 claims description 13
- 108700011259 MicroRNAs Proteins 0.000 claims description 12
- 239000002679 microRNA Substances 0.000 claims description 12
- 230000002452 interceptive effect Effects 0.000 claims description 11
- 238000013518 transcription Methods 0.000 claims description 11
- 230000035897 transcription Effects 0.000 claims description 11
- 230000008439 repair process Effects 0.000 claims description 8
- 230000008685 targeting Effects 0.000 claims description 8
- 239000000126 substance Substances 0.000 claims description 7
- 238000004519 manufacturing process Methods 0.000 claims description 6
- 108091070501 miRNA Proteins 0.000 claims description 6
- 238000012360 testing method Methods 0.000 claims description 6
- 229940000406 drug candidate Drugs 0.000 claims description 5
- 238000012216 screening Methods 0.000 claims description 5
- 238000000338 in vitro Methods 0.000 claims description 2
- 229940088872 Apoptosis inhibitor Drugs 0.000 abstract description 2
- 239000000158 apoptosis inhibitor Substances 0.000 abstract description 2
- 210000004027 cell Anatomy 0.000 description 22
- 210000002901 mesenchymal stem cell Anatomy 0.000 description 21
- 230000004900 autophagic degradation Effects 0.000 description 17
- 210000000130 stem cell Anatomy 0.000 description 17
- 238000002474 experimental method Methods 0.000 description 12
- 230000029663 wound healing Effects 0.000 description 12
- 108091046869 Telomeric non-coding RNA Proteins 0.000 description 10
- 230000035876 healing Effects 0.000 description 10
- 239000000203 mixture Substances 0.000 description 8
- 238000010186 staining Methods 0.000 description 8
- 230000004908 autophagic flux Effects 0.000 description 7
- 210000004957 autophagosome Anatomy 0.000 description 7
- 238000009472 formulation Methods 0.000 description 7
- 239000002243 precursor Substances 0.000 description 7
- 108090000623 proteins and genes Proteins 0.000 description 7
- 101000950671 Chelon ramada Myosin light chain 3, skeletal muscle isoform Proteins 0.000 description 6
- 101001052506 Homo sapiens Microtubule-associated proteins 1A/1B light chain 3A Proteins 0.000 description 6
- 102100024178 Microtubule-associated proteins 1A/1B light chain 3A Human genes 0.000 description 6
- 238000011529 RT qPCR Methods 0.000 description 6
- 239000003937 drug carrier Substances 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- 230000002829 reductive effect Effects 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- 238000001262 western blot Methods 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 239000002773 nucleotide Substances 0.000 description 5
- 125000003729 nucleotide group Chemical group 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- 239000013598 vector Substances 0.000 description 5
- FSASIHFSFGAIJM-UHFFFAOYSA-N 3-methyladenine Chemical compound CN1C=NC(N)=C2N=CN=C12 FSASIHFSFGAIJM-UHFFFAOYSA-N 0.000 description 4
- 239000002552 dosage form Substances 0.000 description 4
- 238000010166 immunofluorescence Methods 0.000 description 4
- 238000003125 immunofluorescent labeling Methods 0.000 description 4
- 239000013612 plasmid Substances 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 238000002965 ELISA Methods 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 238000012228 RNA interference-mediated gene silencing Methods 0.000 description 3
- 206010072170 Skin wound Diseases 0.000 description 3
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 3
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 3
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 230000001684 chronic effect Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 238000000684 flow cytometry Methods 0.000 description 3
- 230000009368 gene silencing by RNA Effects 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 210000002540 macrophage Anatomy 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 102000040430 polynucleotide Human genes 0.000 description 3
- 108091033319 polynucleotide Proteins 0.000 description 3
- 239000002157 polynucleotide Substances 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 230000000069 prophylactic effect Effects 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 238000003757 reverse transcription PCR Methods 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- 210000003491 skin Anatomy 0.000 description 3
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 2
- 102100021569 Apoptosis regulator Bcl-2 Human genes 0.000 description 2
- 101150086017 Bcl2l11 gene Proteins 0.000 description 2
- 108010009992 CD163 antigen Proteins 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- 208000002249 Diabetes Complications Diseases 0.000 description 2
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 101000971171 Homo sapiens Apoptosis regulator Bcl-2 Proteins 0.000 description 2
- 108090000193 Interleukin-1 beta Proteins 0.000 description 2
- 102000003777 Interleukin-1 beta Human genes 0.000 description 2
- 102000003814 Interleukin-10 Human genes 0.000 description 2
- 108090000174 Interleukin-10 Proteins 0.000 description 2
- 102000004889 Interleukin-6 Human genes 0.000 description 2
- 108090001005 Interleukin-6 Proteins 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 241000699660 Mus musculus Species 0.000 description 2
- 102100029438 Nitric oxide synthase, inducible Human genes 0.000 description 2
- 101710089543 Nitric oxide synthase, inducible Proteins 0.000 description 2
- 102100025831 Scavenger receptor cysteine-rich type 1 protein M130 Human genes 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 2
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 2
- 208000025865 Ulcer Diseases 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 230000002886 autophagic effect Effects 0.000 description 2
- 239000012822 autophagy inhibitor Substances 0.000 description 2
- 102000055102 bcl-2-Associated X Human genes 0.000 description 2
- 108700000707 bcl-2-Associated X Proteins 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 230000005540 biological transmission Effects 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 210000004207 dermis Anatomy 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 230000003828 downregulation Effects 0.000 description 2
- 210000002889 endothelial cell Anatomy 0.000 description 2
- 230000003511 endothelial effect Effects 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 239000003925 fat Substances 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- 230000037440 gene silencing effect Effects 0.000 description 2
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 238000003384 imaging method Methods 0.000 description 2
- 230000001771 impaired effect Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 210000002510 keratinocyte Anatomy 0.000 description 2
- 210000003712 lysosome Anatomy 0.000 description 2
- 230000001868 lysosomic effect Effects 0.000 description 2
- 230000035800 maturation Effects 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 238000011580 nude mouse model Methods 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 230000003076 paracrine Effects 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 229920002477 rna polymer Polymers 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 238000009168 stem cell therapy Methods 0.000 description 2
- 238000009580 stem-cell therapy Methods 0.000 description 2
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 231100000397 ulcer Toxicity 0.000 description 2
- 230000002792 vascular Effects 0.000 description 2
- ZPBYVFQJHWLTFB-UHFFFAOYSA-N 3-methyl-7H-purin-6-imine Chemical compound CN1C=NC(=N)C2=C1NC=N2 ZPBYVFQJHWLTFB-UHFFFAOYSA-N 0.000 description 1
- 208000020053 Abnormal inflammatory response Diseases 0.000 description 1
- 102000000412 Annexin Human genes 0.000 description 1
- 108050008874 Annexin Proteins 0.000 description 1
- 108010092776 Autophagy-Related Protein 5 Proteins 0.000 description 1
- 102000016614 Autophagy-Related Protein 5 Human genes 0.000 description 1
- 102100021251 Beclin-1 Human genes 0.000 description 1
- 108090000524 Beclin-1 Proteins 0.000 description 1
- 102000003952 Caspase 3 Human genes 0.000 description 1
- 108090000397 Caspase 3 Proteins 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- 208000009084 Cold Injury Diseases 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 238000000018 DNA microarray Methods 0.000 description 1
- 206010012655 Diabetic complications Diseases 0.000 description 1
- 206010056340 Diabetic ulcer Diseases 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 101150021185 FGF gene Proteins 0.000 description 1
- 108091092584 GDNA Proteins 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 1
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 101000644537 Homo sapiens Sequestosome-1 Proteins 0.000 description 1
- 206010021531 Impetigo Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 206010029113 Neovascularisation Diseases 0.000 description 1
- 238000000636 Northern blotting Methods 0.000 description 1
- 239000002033 PVDF binder Substances 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 102000004245 Proteasome Endopeptidase Complex Human genes 0.000 description 1
- 108090000708 Proteasome Endopeptidase Complex Proteins 0.000 description 1
- 108010026552 Proteome Proteins 0.000 description 1
- 102000014450 RNA Polymerase III Human genes 0.000 description 1
- 108010078067 RNA Polymerase III Proteins 0.000 description 1
- 238000003559 RNA-seq method Methods 0.000 description 1
- 206010037888 Rash pustular Diseases 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 108010057163 Ribonuclease III Proteins 0.000 description 1
- 102000003661 Ribonuclease III Human genes 0.000 description 1
- 108010083644 Ribonucleases Proteins 0.000 description 1
- 102000006382 Ribonucleases Human genes 0.000 description 1
- 102100020814 Sequestosome-1 Human genes 0.000 description 1
- ZSJLQEPLLKMAKR-UHFFFAOYSA-N Streptozotocin Natural products O=NN(C)C(=O)NC1C(O)OC(CO)C(O)C1O ZSJLQEPLLKMAKR-UHFFFAOYSA-N 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 206010053615 Thermal burn Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 241000021375 Xenogenes Species 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000027455 binding Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000029918 bioluminescence Effects 0.000 description 1
- 238000005415 bioluminescence Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 239000007894 caplet Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 239000002771 cell marker Substances 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000005754 cellular signaling Effects 0.000 description 1
- 230000002595 cold damage Effects 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 230000007797 corrosion Effects 0.000 description 1
- 238000005260 corrosion Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000001804 debridement Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000013118 diabetic mouse model Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 208000016097 disease of metabolism Diseases 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000003596 drug target Substances 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 210000004700 fetal blood Anatomy 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 230000019305 fibroblast migration Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 238000003209 gene knockout Methods 0.000 description 1
- 208000004104 gestational diabetes Diseases 0.000 description 1
- 239000006481 glucose medium Substances 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000005090 green fluorescent protein Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000010185 immunofluorescence analysis Methods 0.000 description 1
- 238000012744 immunostaining Methods 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000007915 intraurethral administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000007914 intraventricular administration Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000004630 mental health Effects 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 206010062198 microangiopathy Diseases 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 210000002894 multi-fate stem cell Anatomy 0.000 description 1
- 230000000955 neuroendocrine Effects 0.000 description 1
- 210000004412 neuroendocrine cell Anatomy 0.000 description 1
- 108091027963 non-coding RNA Proteins 0.000 description 1
- 102000042567 non-coding RNA Human genes 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 210000004789 organ system Anatomy 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000006201 parenteral dosage form Substances 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 208000033808 peripheral neuropathy Diseases 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 1
- 230000001124 posttranscriptional effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 239000003531 protein hydrolysate Substances 0.000 description 1
- 208000029561 pustule Diseases 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 108010054624 red fluorescent protein Proteins 0.000 description 1
- 238000004153 renaturation Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 108091006024 signal transducing proteins Proteins 0.000 description 1
- 102000034285 signal transducing proteins Human genes 0.000 description 1
- 238000007390 skin biopsy Methods 0.000 description 1
- -1 small molecule compounds Chemical class 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 229960001052 streptozocin Drugs 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000006203 subcutaneous dosage form Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 238000004627 transmission electron microscopy Methods 0.000 description 1
- 238000013042 tunel staining Methods 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 210000003954 umbilical cord Anatomy 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/136—Screening for pharmacological compounds
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Diabetes (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Analytical Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Pathology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明公开了Lnc‑CCKAR‑5在制备抑制MSCs凋亡、提高治疗效果的药物中的应用,本发明首次发现抑制Lnc‑CCKAR‑5的表达能够抑制高糖诱导的MSCs凋亡,可以Lnc‑CCKAR‑5为靶点制备高糖环境下MSCs的凋亡抑制剂,并可以Lnc‑CCKAR‑5为靶点开发促进糖尿病创面修复的药物,具有良好的临床应用价值。
Description
技术领域
本发明属于生物医药技术领域,具体地,本发明涉及Lnc-CCKAR-5在制备抑制MSCs凋亡、提高治疗效果的药物中的应用。
背景技术
糖尿病(Diabetes mellitus,DM)是以慢性高血糖为特征的代谢性疾病,临床常见的类型主要包括1型糖尿病、2型糖尿病和妊娠期糖尿病。作为一种全球性疾病,糖尿病已经对全人类的身心健康构成了重大威胁。糖尿病创面是糖尿病最难治的并发症之一,糖尿病创面的特点是趋化因子和血管化不足,成纤维细胞迁移和增殖减少,以及异常的炎症反应。目前针对糖尿病创面的常规治疗方法包括定制辅料、外科清创、负压治疗以及抗生素和高压氧治疗等。但是,仍有近50%的患者无法通过常规治疗方法得到治愈。糖尿病创面愈合延迟的因素众多,包括周围神经病变、免疫反应缺陷、周围微血管病、血红蛋白糖基化引起的组织氧输送不足、红细胞变化、Ⅲ型和Ⅰ型皮肤胶原比例改变、糖尿病皮肤的生物力学改变、成纤维细胞和角质细胞迁移、扩增能力减弱、角质细胞和内皮细胞凋亡等。导致糖尿病溃疡的重要因素是血液循环不良和伤口愈合障碍,因此,改善创面微环境和改善血管生成对于糖尿病创面的修复和愈合具有重要意义。
间充质干细胞(Mesenchymal stem cells,MSCs)是一种多能干细胞,它具有干细胞的所有共性,即自我更新和多向分化能力,被认为是各种组织再生治疗中最有希望的干细胞之一。近年来,大量的实验研究证明了多种组织来源的间充质干细胞可以促进糖尿病创面的愈合,例如:骨髓、脂肪、脐带血和皮肤组织来源的间充质干细胞。目前认为间充质干细胞促进创面愈合主要是靠旁分泌途径分泌丰富的“蛋白质组”包括:生长因子、miRNA、蛋白酶体和细胞外囊泡等,间充质干细胞旁分泌在损伤模型中可发挥促进增殖和抑制炎症等重要作用,然而,在高糖环境下,容易诱导间充质干细胞的凋亡,进而降低其对糖尿病创面的治疗效果,因此,如何抑制高糖诱导的间充质干细胞的凋亡是目前本领域亟待解决的技术问题之一。有鉴于此,本申请的目的在于研究LincRNA对高糖环境下间充质干细胞凋亡的调控作用,从而寻找促进糖尿病创面修复的药物靶标。
目前,尚未见Lnc-CCKAR-5在抑制间充质干细胞凋亡、促进糖尿病创面修复中的应用的相关研究或报道。
发明内容
为了弥补现有技术存在的不足,本发明的目的在于提供Lnc-CCKAR-5在制备抑制MSCs凋亡、提高治疗效果的药物中的应用。
为了实现上述目的,本发明采用了如下技术方案:
本发明的第一方面提供了抑制Lnc-CCKAR-5表达的试剂在制备抑制高糖诱导的MSCs凋亡的药物中的应用。
进一步,所述试剂包括抑制Lnc-CCKAR-5表达或转录的干扰分子。
进一步,所述试剂包括靶向Lnc-CCKAR-5的siRNA、shRNA、dsRNA、微小RNA、反义核酸中的至少一种,或能表达或形成所述siRNA、shRNA、dsRNA、微小RNA、反义核酸的构建物。
进一步,所述Lnc-CCKAR-5的核苷酸序列如SEQ ID NO:9所示。
在本发明的具体实施方案中,所述高糖是指培养基中葡萄糖浓度或实验动物血糖浓度≥16.7mmol/L。
本发明的第二方面提供了抑制Lnc-CCKAR-5表达的试剂在制备促进糖尿病创面修复的药物中的应用。
进一步,所述试剂包括抑制Lnc-CCKAR-5表达或转录的干扰分子。
进一步,所述试剂包括靶向Lnc-CCKAR-5的siRNA、shRNA、dsRNA、微小RNA、反义核酸中的至少一种,或能表达或形成所述siRNA、shRNA、dsRNA、微小RNA、反义核酸的构建物。
进一步,所述药物组合物还包括药学上可接受的载体和/或辅料。
进一步,所述药学上可接受的载体和/或辅料在Remington's PharmaceuticalSciences(19th ed.,1995)中有详细的记载,这些物质根据需要用于帮助配方的稳定性或有助于提高活性或其生物有效性或在口服的情况下产生可接受的口感或气味,在这种药物组合物中可以使用的制剂可以是其原始化合物本身的形式,或任选地使用其药物学可接受的盐的形式,如此配制的药物组合物根据需要可选择本领域技术人员已知的任何适当的方式将药物对有需要的受试者进行给药。在本发明的具体实施方案中,所述受试者优选为人。
在一些实施方案中,本发明所述的创面并不局限于糖尿病创面,还包括各种常见的皮肤创面,所述皮肤创面包括但不限于:烧伤、烫伤、冻伤、刀伤、化学腐蚀、炎症伤口、溃烂、糖尿病并发症溃烂、脓包、黄水疮的创面。
本发明的第三方面提供了一种抑制高糖诱导的MSCs凋亡或促进糖尿病创面修复的药物组合物。
进一步,所述药物组合物包含抑制Lnc-CCKAR-5表达的试剂;
优选地,所述试剂包括抑制Lnc-CCKAR-5表达或转录的干扰分子;
更优选地,所述试剂包括靶向Lnc-CCKAR-5的siRNA、shRNA、dsRNA、微小RNA、反义核酸中的至少一种,或能表达或形成所述siRNA、shRNA、dsRNA、微小RNA、反义核酸的构建物。
进一步,所述药物组合物还包括药学上可接受的载体和/或辅料。
进一步,所述药学上可接受的载体和/或辅料包括药学上可接受的载体、稀释剂、填充剂、结合剂及其它赋形剂,这依赖于给药方式及所设计的剂量形式。本领域技术人员已知的治疗惰性的无机或有机的载体包括但不限于:乳糖、玉米淀粉或其衍生物、滑石、植物油、蜡、脂肪、多羟基化合物(例如聚乙二醇、水、蔗糖、乙醇、甘油),诸如此类,各种防腐剂、润滑剂、分散剂、矫味矫臭剂、湿润剂、甜味剂、香味剂、乳化剂、悬浮剂、保存剂、抗氧化剂、着色剂、稳定剂、盐、缓冲液,诸如此类的也可加入其中,适合的药学上可接受的载体和/或辅料在Remington's Pharmaceutical Sciences(19th ed.,1995)中有详细的记载。
进一步,所述药物组合物适合的给药剂量根据制剂化方法、给药方式、患者的年龄、体重、性别、病态、饮食、给药时间、给药途径、排泄速度及反应灵敏性之类的因素而可以进行多种处方,通常,熟练的医生能够容易地决定处方及处方对所希望的治疗或预防有效的给药剂量。
进一步,所述药物组合物根据需要可以制备成多种临床药物剂型以作为抑制高糖诱导的MSCs凋亡的药物和/或促进糖尿病创面修复的药物,所述药物剂型包括但不限于:非肠道给药的剂型或者口服制剂,所述的非肠道给药剂型包括注射剂、气雾剂、栓剂或皮下给药剂型;所述口服制剂包括片剂、胶囊剂、丸剂、颗粒剂、微囊片剂、混悬剂、滴丸、口服液体制剂,在本发明的具体实施方案中,所述药物剂型优选为非肠道给药剂型。
进一步,所述药物组合物的施用途径不受限制,只要它能发挥期望的治疗效果或预防效果或抑制间充质干细胞凋亡的效果即可,所述施用途径包括但不限于:局部的、通过皮肤、静脉内、腹膜内、眼内、动脉内、肺内、口服、小泡内、肌肉内、气管内、皮下的、吸入、通过胸膜、通过粘膜、皮肤、肠胃、关节内、心室内、直肠、阴道、颅骨内、尿道内、肝内。在某些情况下,可以系统地给药,在某些情况下,可以局部地给药。
进一步,所述药物组合物的剂量不受限制,只要获得期望的治疗效果或预防效果或抑制间充质干细胞凋亡的效果即可,可以依据症状、性别、年龄等来恰当地确定。本发明所述的药物或药物组合物的剂量可以使用例如对疾病的治疗效果或预防效果或者对间充质干细胞凋亡的抑制效果作为指标来详细确定。
本发明的第四方面提供了一种体外抑制高糖诱导的MSCs凋亡的方法。
进一步,所述方法包括向MSCs体系中施用有效量的抑制Lnc-CCKAR-5表达的试剂;
优选地,所述试剂包括抑制Lnc-CCKAR-5表达或转录的干扰分子;
更优选地,所述试剂包括靶向Lnc-CCKAR-5的siRNA、shRNA、dsRNA、微小RNA、反义核酸中的至少一种,或能表达或形成所述siRNA、shRNA、dsRNA、微小RNA、反义核酸的构建物。
在本发明的具体实施方案中,本发明通过细胞实验和动物实验进一步证明了抑制Lnc-CCKAR-5的表达能够显著抑制高糖诱导的MSCs的凋亡,进一步能够提高MSCs对糖尿病创面的治疗效果。
本发明的第五方面提供了Lnc-CCKAR-5在筛选抑制高糖诱导的MSCs凋亡的候选药物或促进糖尿病创面修复的候选药物中的应用。
进一步,所述候选药物的筛选方法如下本发明第六方面所述。
本发明的第六方面提供了一种筛选抑制高糖诱导的MSCs凋亡的候选药物或促进糖尿病创面修复的候选药物的方法。
进一步,所述方法包括如下步骤:
(1)用测试物质处理表达或含有Lnc-CCKAR-5的体系;
(2)检测所述体系中Lnc-CCKAR-5的表达;
(3)选择能够抑制Lnc-CCKAR-5表达的测试物质为候选药物。
进一步,所述体系选自:细胞体系、亚细胞体系、溶液体系、组织体系、器官体系或动物体系。
进一步,步骤(1)中所述的测试物质包括但不限于:针对Lnc-CCKAR-5设计的干扰分子、核酸抑制物、小分子化合物等。
进一步,步骤(2)中所述的检测Lnc-CCKAR-5表达的方法包括但不限于:反转录聚合酶链式反应(RT-PCR)、竞争性RT-PCR、实时RT-PCR、核糖核酸酶保护测定(RPA)、RNA印迹和DNA芯片等方法。
进一步,检测Lnc-CCKAR-5表达的试剂包括但不限于:引物、探针或反义核苷酸。本领域技术人员可基于Lnc-CCKAR-5的序列信息设计得到能够特异性结合至Lnc-CCKAR-5的引物、探针或反义核苷酸。
进一步,步骤(3)中所述选择的候选药物为与在该候选药物不存在时检测到的Lnc-CCKAR-5的表达水平相比,该候选药物存在时能够抑制Lnc-CCKAR-5的表达水平的测试物质。
为了进一步阐述本发明,此处对本发明中涉及到的技术和科学术语进行如下定义:
在本文中使用,术语“siRNA”是指小干扰性核糖核酸,即相对短长度的双链核酸或任选地其较长前体。在一些实施方式中,本发明中可用siRNA的长度优选为约20至50bp的长度。但是,在此对可用siRNA的长度没有特殊限制。例如,siRNA可以最初以前体形式存在于细胞中,所述前体形式与递送至靶细胞时或递送至靶细胞后表现和发挥基因沉默活性的siRNA的最终或加工形式实质上不同。例如,siRNA的前体形式可以包括前体序列元件,所述元件在递送时或递送后就会被加工、降解、改变或切割,以产生在细胞内有介导基因沉默活性的siRNA。在一些实施方式中,可用的siRNA具有的前体长度为例如约100至200个碱基对或50至100个碱基对或少于约50个碱基对,其在靶细胞内会产生有活性的,加工过的siRNA。在其它实施方式中,可用的siRNA或siRNA前体长度约为10至49bp或15至35bp或约21至30bp。
在本文中使用,术语“shRNA”是指短发夹RNA,shRNA包括两个短反向重复序列。克隆到shRNA表达载体中的shRNA包括两个短反向重复序列,中间由一茎环(loop)序列分隔的,组成发夹结构,由polⅢ启动子控制。随后再连上5-6个T作为RNA聚合酶Ⅲ的转录终止子。shRNA可以稳定地整合到细胞的基因组中,允许长期基因敲除。
在本文中使用,术语“dsRNA”是指双链核糖核酸,由两条互补链复性形成的RNA分子,可以被Dicer酶切割形成siRNA。dsRNA通过RNA干扰(RNAi)来抑制基因的表达,dsRNA不需要与靶基因序列具有100%的同源性,只要它可抑制靶基因表达即可。
在本文中使用,术语“微小RNA”是指微小核糖核酸(miRNA),微小RNA是长约22nt的非编码RNA,广泛存在于从病毒到人类的各种生物中。成熟的miRNA主要作用是对基因转录后水平进行负向调节,通过引起其靶mRNA的降解或翻译过程的中断而参与细胞增殖、凋亡、免疫、神经内分泌以及干细胞分化等众多生命过程。
在本文中使用,术语“反义核酸”是指含有与编码Lnc-CCKAR-5的序列互补的核酸,可以和“反义核苷酸”互换使用。反义核酸可以由DNA、RNA或二者组成。反义核酸可含有非互补碱基,只要它能够在严格条件下特异性杂交即可。当将反义核酸引入细胞时,它结合靶多核苷酸并抑制转录、RNA加工、或稳定性。除反义多核苷酸之外,反义核酸还包括多核苷酸模拟物,它含有经过修饰的主链、和3’和5’端部分。这样的反义核酸可以根据Lnc-CCKAR-5的序列信息来恰当设计并使用本领域技术人员公知的方法来生成。
相对于现有技术,本发明具有的优点和有益效果:
本发明首次提出了Lnc-CCKAR-5抑制剂在抑制间充质干细胞凋亡、提高治疗效果中的用途。本发明首次发现抑制Lnc-CCKAR-5的表达能够抑制高糖诱导的间充质干细胞的凋亡,可以Lnc-CCKAR-5为靶点制备高糖环境下间充质干细胞的凋亡抑制剂,并可以Lnc-CCKAR-5为靶点开发促进糖尿病创面修复的药物,本发明为糖尿病创面的治疗提供了理论基础和新的治疗思路,具有良好的应用前景。
附图说明
图1为LincRNA在高糖处理的干细胞中的表达情况及其在高糖环境下发挥调节hUCMSCs自噬和凋亡作用的结果图,其中,A图:用高葡萄糖培养基处理的hUCMSCs中Lnc-CCKAR-5的表达谱,B图:差异表达的LincRNAs火山图,筛选标准:|log2FC|>1.0,C图:通过免疫荧光染色检测LC3蛋白的表达(每组n=3),D图:Western blot检测过表达Lnc-CCKAR-5的hUCMSCs中ATG5、Beclin1、LC3-Ⅰ/LC3-Ⅱ、P62的表达,E图和F图:引入Lnc-CCKAR-5后的自噬通量结果图和统计图,G图和H图:通过透射电子显微镜观察hUCMSCs中的自噬体结果图和统计图,比例尺:1μm;
图2为间充质干细胞中Lnc-CCKAR-5的低表达通过激活自噬来抑制细胞凋亡,其中,A图:通过免疫荧光染色检测用自噬抑制剂3-MA(5mM)或Baf-A1(100nM)处理的低表达Lnc-CCKAR-5的hUCMSCs或对照细胞(hUCMSCs)中LC3蛋白的表达(每组n=3),B图和C图:Annexin-Fitc/PI染色,流式细胞术分析细胞的凋亡情况(每组n=3),D图和E图:TUNEL染色分析细胞的凋亡情况(每组n=3),F图和G图:Western Blot检测Bim、Bcl-2、Bax和GAPDH的表达,数据表示为三个独立实验的平均值±SD,其中,**P<0.01,***P<0.001;图3为Lnc-CCKAR-5调节干细胞治疗糖尿病创面愈合的能力,其中,A图和B图:hUCMSCs用LV包装的Lnc-CCKAR-5siRNA载体(LV-Lnc-CCKAR-5KD)、Lnc-CCKAR-5OE载体(LV-Lnc-CCKAR-5OE)和对照载体(LV-Control)分别感染,接种在患有慢性伤口的糖尿病小鼠中,用CM-Dil染料标记干细胞分布的结果图和统计图,C图和D图:皮肤创面的大体外观图和愈合指数统计图,E图和F图:通过HE染色和Masson染色观察伤口愈合7天的结果图和统计图,G图和H图:巨噬细胞M1和M2的免疫荧光染色结果图和统计图,数据表示为三个独立实验的平均值±SD,其中,*P<0.05,**P<0.01,***P<0.001;
图4为Lnc-CCKAR-5调节干细胞治疗糖尿病创面愈合的能力,其中,A图和B图:hUCMSCs用LV包装的Lnc-CCKAR-5siRNA载体(LV-Lnc-CCKAR-5KD)、Lnc-CCKAR-5OE载体(LV-Lnc-CCKAR-5OE)和对照载体(LV-Control)感染,接种在患有慢性伤口的糖尿病小鼠中,新生血管内皮细胞组织结构的免疫荧光染色结果图和统计图,C图和D图:细胞凋亡和自噬的免疫荧光结果图和统计图,E图:ELISA检测IL-1β、TNF-α、IL-10、IL-6、FGF和VEGF等创面因子的表达量,数据表示为三个独立实验的平均值±SD,其中,*P<0.05,**P<0.01,***P<0.001。
具体实施方式
下面结合具体实施例,进一步阐述本发明,仅用于解释本发明,而不能理解为对本发明的限制。本领域的普通技术人员可以理解为:在不脱离本发明的原理和宗旨的情况下可以对这些实施例进行多种变化、修改、替换和变型,本发明的范围由权利要求及其等同物限定。下列实施例中未注明具体条件的实验方法,通常按照常规条件或按照厂商所建议的条件实施检测。
实施例Lnc-CCKAR-5抑制MSCs的凋亡、提高MSCs对糖尿病创面的治疗效果
1、实验方法
1.1高糖处理和转录组测序
实验前将人脐带间充质干细胞(hUCMSCs,MSCs)在含有高葡萄糖(25mM)的无血清DMEM培养基中培养48h。使用RiboMinus试剂盒(Invitrogen,上海,中国)去除从hUCMSC分离的总RNA中的rRNA。利用TruSeq Stranded Total RNA HT样品制备试剂盒(Part number:15031048;Illumina,San Diego,CA)制备文库。通过Q30评分对获得的双端reads进行质量控制。使用DCC软件(version 0.9.0,Max Planck Institute for Biology of Ageing,Cologne,Germany)对高质量的reads进行LincRNA鉴定。
1.2质粒构建及小干扰RNA干扰实验
Lnc-CCKAR-5过表达质粒和抑制剂由Genome-ditech公司(上海,中国)合成。Lnc-CCKAR-5的特异性干扰RNA(si-Lnc-CCKAR-5)序列由GenePharma公司(上海,中国)生产,此外,还包括空质粒或乱序质粒作为对照。所述干扰序列si-Lnc-CCKAR-5的具体序列信息如下:
si-Lnc-CCKAR-5F:AACUUCUAUCAUCUAGAUGUC(SEQ ID NO:1)
si-Lnc-CCKAR-5R:CAUCUAGAUGAUAGAAGUUCC(SEQ ID NO:2)
1.3RT-PCR和qRT-PCR
使用HiScript II Q RT SuperMixfor qPCR(+gDNA wiper)(Vazyme,Nanjing,China)反转录RNA。使用AceQ qPCR SYBR Green Master Mix(Vazyme,南京,中国)进行qRT-PCR实验。LncRNA和mRNA水平通过GAPDH标准化,具体的引物序列如表1所示。
表1引物序列
1.4透射电子显微镜
透射电镜观察MSCs凋亡的形态学特征。将hUCMSCs细胞(1×106细胞/孔)接种在6孔板上并用相应试剂处理24h后,用戊二醛固定。采用Hitachi TEM系统采集图像。
1.5Western blot分析
等量的总蛋白裂解液(20μg)经6–15% SDS-PAGE分离后转移至PVDF膜上。封闭非特异性结合后,一抗(1:1000稀释)4℃孵育过夜,二抗(1:2000稀释;Bioword)室温孵育1.5h。采用Bio-Rad ChemiDoc XRS系统检测条带。
1.6蛋白质分子量的测量
将纯化的重组蛋白进行系列稀释后用于蛋白质印迹分析,以生成标准曲线。根据标准曲线对已知数量的细胞中目的蛋白的质量进行定量。使用ImageJ程序对蛋白质印迹信号强度进行定量。蛋白质分子量由以下网站(http://www.protein tech.com/bio/)的蛋白质分子量计算器计算得到。
1.7免疫荧光
将hUCMSCs细胞接种在24孔细胞培养板中,然后用相应的试剂处理24h。收集细胞并用4% PFA固定15min,用1% BSA孵育20min,之后在4℃的条件下过夜。随后将其与FITC标记的二抗在室温下孵育2h。最后用DAPI(KeyGEN BioTECH,KGA215-50)对细胞核进行染色,并用荧光显微镜拍照。
1.8自噬通量测定
用串联荧光mRFP-eGFP-LC3 Beadenovirus(HanBio,上海,中国)感染hUCMSCs,并用DAPI对细胞核进行染色。人工计算绿色荧光蛋白和单体红色荧光蛋白表达点。
1.9流式细胞仪测定
经处理后的MSCs用Annexin fitc/PI(KeyGen Biotech,Nanjing,China)进行染色,并通过流式细胞术分析以确定细胞凋亡率。
1.10TUNEL法检测细胞凋亡
采用TUNEL analysis(Roche Diagnostics,中国上海)鉴定MSCs的凋亡。分析细胞凋亡的比例。
1.11糖尿病伤口模型的构建及治疗
所有程序参照徐州医科大学动物护理和使用指南(中国徐州)执行。链脲佐菌素(Streptozotocin,STZ)(Sigma-Aldrich,上海,上海)用于建立1型糖尿病模型。每组由6只裸鼠组成,腹膜内注射150mg/kg链脲佐菌素。以至少4周血清葡萄糖水平>16.7mmol/L为糖尿病小鼠模型构建成功。对小鼠模型进行麻醉后,在小鼠背部切取直径为1.2cm的皮肤创面。hUCMSCs(1×107)在注射前用荧光染料CM-Dil(Invitrogen)预先标记,并检测hUCMSCs在伤口中的存活率。在分别注射si-Lnc-CCKAR-5和Lnc-CCKAR-5过表达的hUCMSCs后第0天和第3天检测CM-Dil染色效率。小鼠的生物发光成像采用Xenogen IVIS200成像系统(Caliper Life Sciences,Hopkinton,MA),激发波长为420nm,发射波长为480nm。
1.12组织学伊红染色和Masson染色
治疗2周后处死小鼠,收集创面和邻近部位的皮肤活检。用H&E(Sigma-Aldrich)和Masson三色(Sigma-Aldrich)对采集的各组织进行染色。采用Masson三色染色法检测新生真皮厚度,行H&E染色评估再上皮化率。
1.13伤口愈合评估
在收集之前,在注射Lnc-CCKAR-5hUCMSCs后第0天和第7天,在等焦点的数字化图像上识别并记录每只小鼠背部受伤区域的尺寸。伤口愈合率的计算公式如下:伤口闭合指数(%)=(1-未愈合伤口面积/原始伤口面积)±100%。
1.14免疫荧光分析
切片在-20℃丙酮中固定后进行免疫荧光。应用抗CD31,Ki-67,iNOS,CD163,LC3和Caspase3抗体(1:50,Cell Signaling Technology)进行免疫荧光染色。细胞核用DAPI(Abcam,Cambridge,United Kingdom)进行染色。使用安装的Camedia Master数码相机(Olympus,Tokyo,Japan)获得免疫荧光图像。
1.15统计数据
数据表示为平均值±标准差(SD)。使用Prism软件(GraphPad Software 8)进行统计学分析,采用方差分析和Student's t检验比较两个实验组,P<0.05被认为具有统计学意义。
2、实验结果
2.1LncRNA在高糖处理的干细胞中表达下调,并在高糖环境中发挥调控MSCs自噬和凋亡的作用
为了探究LncRNA在高糖环境中对干细胞的影响,本发明将hUCMSCs在高糖环境中处理8h后进行高通量RNA测序,以检测高糖环境中干细胞的转录谱(见图1A),选择变化较大的LncRNA进行实时定量PCR(qRT-PCR)检测,确定Lnc-CCKAR-5(ENST00000507759)为变化最大的LncRNA(见图1B),其核苷酸序列如下所示:
GCACTCATTCTCCAAGCCCACATGTGATCCGATTCATCCAGTACACCAAGTGTCCAGGGACATCTAGATGATAGAAGTTCCTTCAGATGGGTCCCTGGTGTGAGGGTGTCCTGTATCAGACTGCCTATTGAAGTTCAACCTGTGGTTCAAGACAGGATCTCATTCAGAATACTACTTTCATTCAGGCTGGAGTGCAGTGGCATGATCTTAGCTCTCTGCAACTTCCGCCTCCTGGGCTCAAGCGATTCTCCTGTCTCAGGCTCCGGAGTAGCTGGGACTACAGGCATGCGCCACAACACCAGGGAAAAAAACAAACCAACCAACAAACTGAGCCTGAAACTGATAACACAGATACGTACAGCATCATATTTAAGTAACCAATCGGAATTATTGCAGTGGAGATGTTTTATTGGTGGGAAATACGGTATCACACCATTTCAGACATCAGGAGATAATTATCCCTGTCTTCTCGGAACCAGCTTCTTCAAAGGAGTCAGGAATTATTTATGATAGAAACTACTGAAACAATACTAAGGAGTTCATAGGTTGCTGAGAAGGTAGCTTCCTGCCCTCTGCTTGAGGAACACGGATGGAAGAAAGGAGAAGATCTGGTCAACACAGCTCCTGAAATGCTGATTAAGCATTATGGGATTTAAGGTTTCCTGGCCAAGTCTGAGCTAAAATGTTAACACTCCTGAAGAACACCATAAAGAAAGAAAAACAAAA(SEQ ID NO:9)。
自噬是保护hUCMSCs免于凋亡的重要机制,本发明研究了Lnc-CCKAR-5在高糖环境中对自噬的影响。LC3免疫染色和Western blot实验的结果证明在高糖处理的干细胞中,Lnc-CCKAR-5的高表达显著抑制了高糖环境下自噬体的产生(见图1C),而抑制Lnc-CCKAR-5的表达显著促进了高糖环境中自噬溶酶体的产生(见图1D)。评估自噬通量以区分自噬诱导激活和晚期自噬抑制,这两者都会导致自噬过程的特征蛋白LC3B-Ⅱ的增加。首先,高糖环境导致干细胞发生自噬保护,自噬通量显著增加;其次,P62/SQSTM1在自噬通量低的细胞中积累,而P62在过表达Lnc-CCKAR-5的干细胞中显著增加;同时,mRFP/mCherry-eGFP-LC3B用于监测自噬体的成熟,自噬体在酸性溶酶体环境中由于eGFP荧光被抑制而被标记为黄色,成熟的自噬溶酶体标记为红色,也即黄色是自噬前体,融合后荧光猝灭,因此,成熟的自噬溶酶体被标记为红色。与高糖环境相比,过表达Lnc-CCKAR-5的细胞中自噬溶酶体和自噬通量显著降低,表明Lnc-CCKAR-5能够抑制自噬成熟并显著降低自噬通量(见图1E、F);最后,敲低Lnc-CCKAR-5的细胞中自噬溶酶体的比例显著上调,红色荧光增强,证明了Lnc-CCKAR-5参与这一过程(见图1G、H)。
2.2细胞中Lnc-CCKAR-5的低表达通过激活自噬抑制细胞凋亡
为了探究自噬活性对细胞活性的影响,本发明用自噬抑制剂3-甲基腺嘌呤(3-MA)(5mM)和巴弗洛霉素A1(Baf-A1)(100nM)处理干细胞,然后敲除Lnc-CCKAR-5,LC3的免疫荧光结果显示,使用3-甲基腺嘌呤和巴弗洛霉素A1处理后,LC3的荧光强度降低,表明自噬受到显著抑制。流式细胞术分析结果显示,敲除Lnc-CCKAR-5可通过促进干细胞自噬来抑制细胞凋亡(见图2A、B、C),这些结果与通过TUNEL和Western blot检测到的Bim、Bcl-2和Bax信号蛋白的表达结果一致(见图2D、E、F、G),以上结果表明Lnc-CCKAR-5诱导的细胞凋亡与自噬激活有关。
2.3Lnc-CCKAR-5调节干细胞治疗糖尿病创面愈合的能力
本发明研究了Lnc-CCKAR-5对hUCMSCs在糖尿病裸鼠创面修复中的作用。敲除Lnc-CCKAR-5的hUCMSCs在单次注射后存活更多,而过表达的hUCMSCs存活率明显较低(见图3A、B)。然后,本发明评估了伤口愈合的程度,从拍摄的过程中发现,si-Lnc-CCKAR-5组的伤口愈合明显加快,愈合程度在第7天达到最高,反之,过表达Lnc-CCKAR-5组的伤口愈合较差(见图3C、D)。最后,HE结果显示敲除Lnc-CCKAR-5后,真皮层厚度远高于其他组,Masson染色结果显示敲除Lnc-CCKAR-5后,胶原纤维排列程度和颜色也远高于其他干细胞处理组(见图3E、F)。
有研究表明,糖尿病创面的愈合与巨噬细胞的调控显著相关,M1型细胞的增加可抑制创面的愈合,而M2型细胞的增加可促进创面的愈合。据此,本发明进一步评估了糖尿病小鼠对创面巨噬细胞的调节作用。Lnc-CCKAR-5敲除组M1标记物iNOS显著低于其他组,而M2细胞标记物CD163显著高于其他组(见图3G、H)。
创面愈合的速度与新生血管的形成直接相关,本发明经实验研究得到的创面血管愈合评价结果如下:Lnc-CCKAR-5敲除组血管内皮活性远远大于其他组,生成量更大,而Lnc-CCKAR-5过表达组的血管内皮新生血管明显受到抑制(见图4A、B)。随后,本发明对创面上干细胞的自噬和凋亡进行了分析,结果显示,Lnc-CCKAR-5敲低组的细胞凋亡明显减少,与如前所得出的结论一致(见图4C、D)。最后,ELISA的实验结果表明,创面上VEGF和EGF相关生长因子在敲除Lnc-CCKAR-5后显著升高,同时IL-10也随之升高而促炎因子IL-1β、TNF-α和IL-6则明显下降(见图4E)。
以上结果表明了Lnc-CCKAR-5能够调节干细胞治疗糖尿病创面愈合的能力,抑制Lnc-CCKAR-5的表达能够显著抑制高糖诱导的间充质干细胞的凋亡,并显著提高其对糖尿病创面的治疗效果。
上述实施例的说明只是用于理解本发明的方法及其核心思想。应当指出,对于本领域的普通技术人员来说,在不脱离本发明原理的前提下,还可以对本发明进行若干改进和修饰,这些改进和修饰也将落入本发明权利要求的保护范围内。
Claims (10)
1.抑制Lnc-CCKAR-5表达的试剂在制备抑制高糖诱导的MSCs凋亡的药物中的应用。
2.根据权利要求1所述的应用,其特征在于,所述试剂包括抑制Lnc-CCKAR-5表达或转录的干扰分子。
3.根据权利要求2所述的应用,其特征在于,所述试剂包括靶向Lnc-CCKAR-5的siRNA、shRNA、dsRNA、微小RNA、反义核酸中的至少一种,或能表达或形成所述siRNA、shRNA、dsRNA、微小RNA、反义核酸的构建物。
4.抑制Lnc-CCKAR-5表达的试剂在制备促进糖尿病创面修复的药物中的应用。
5.根据权利要求4所述的应用,其特征在于,所述试剂包括抑制Lnc-CCKAR-5表达或转录的干扰分子。
6.根据权利要求5所述的应用,其特征在于,所述试剂包括靶向Lnc-CCKAR-5的siRNA、shRNA、dsRNA、微小RNA、反义核酸中的至少一种,或能表达或形成所述siRNA、shRNA、dsRNA、微小RNA、反义核酸的构建物。
7.一种抑制高糖诱导的MSCs凋亡或促进糖尿病创面修复的药物组合物,其特征在于,所述药物组合物包含抑制Lnc-CCKAR-5表达的试剂;
优选地,所述试剂包括抑制Lnc-CCKAR-5表达或转录的干扰分子;
更优选地,所述试剂包括靶向Lnc-CCKAR-5的siRNA、shRNA、dsRNA、微小RNA、反义核酸中的至少一种,或能表达或形成所述siRNA、shRNA、dsRNA、微小RNA、反义核酸的构建物。
8.一种体外抑制高糖诱导的MSCs凋亡的方法,其特征在于,所述方法包括向MSCs体系中施用有效量的抑制Lnc-CCKAR-5表达的试剂;
优选地,所述试剂包括抑制Lnc-CCKAR-5表达或转录的干扰分子;
更优选地,所述试剂包括靶向Lnc-CCKAR-5的siRNA、shRNA、dsRNA、微小RNA、反义核酸中的至少一种,或能表达或形成所述siRNA、shRNA、dsRNA、微小RNA、反义核酸的构建物。
9.Lnc-CCKAR-5在筛选抑制高糖诱导的MSCs凋亡的候选药物或促进糖尿病创面修复的候选药物中的应用。
10.一种筛选抑制高糖诱导的MSCs凋亡的候选药物或促进糖尿病创面修复的候选药物的方法,其特征在于,所述方法包括如下步骤:
(1)用测试物质处理表达或含有Lnc-CCKAR-5的体系;
(2)检测所述体系中Lnc-CCKAR-5的表达;
(3)选择能够抑制Lnc-CCKAR-5表达的测试物质为候选药物。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202310541455.3A CN116407636B (zh) | 2023-05-15 | 2023-05-15 | Lnc-CCKAR-5在制备促进糖尿病创面修复的药物中的应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202310541455.3A CN116407636B (zh) | 2023-05-15 | 2023-05-15 | Lnc-CCKAR-5在制备促进糖尿病创面修复的药物中的应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN116407636A true CN116407636A (zh) | 2023-07-11 |
CN116407636B CN116407636B (zh) | 2023-10-20 |
Family
ID=87049498
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202310541455.3A Active CN116407636B (zh) | 2023-05-15 | 2023-05-15 | Lnc-CCKAR-5在制备促进糖尿病创面修复的药物中的应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN116407636B (zh) |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005059544A1 (en) * | 2003-12-12 | 2005-06-30 | Bayer Healthcare Ag | Diagnostics and therapeutics for diseases associated with g protein-coupled receptor cckar (cckar) |
WO2005073398A1 (ja) * | 2004-01-30 | 2005-08-11 | Sumitomo Chemical Company, Limited | 脂肪量増加抑制能力の検定方法 |
US20050276804A1 (en) * | 2004-06-14 | 2005-12-15 | Wisconsin Alumni Research Foundation | Method for preventing or treating cardiac hypertrophy |
WO2007137239A2 (en) * | 2006-05-19 | 2007-11-29 | The Scripps Research Institute | Treatment of protein misfolding |
EP2052088A2 (en) * | 2006-08-02 | 2009-04-29 | Genizon Biosciences | Genemap of the human genes associated with psoriasis |
CN101838689A (zh) * | 2010-01-14 | 2010-09-22 | 广州市妇女儿童医疗中心 | 一种快速诊断染色体数目异常的多重qf-pcr str检测体系 |
CN110327363A (zh) * | 2019-06-11 | 2019-10-15 | 华中科技大学同济医学院附属同济医院 | 基于hsa-miR-320a的防治糖尿病的药物及其筛选方法和制备方法 |
-
2023
- 2023-05-15 CN CN202310541455.3A patent/CN116407636B/zh active Active
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005059544A1 (en) * | 2003-12-12 | 2005-06-30 | Bayer Healthcare Ag | Diagnostics and therapeutics for diseases associated with g protein-coupled receptor cckar (cckar) |
WO2005073398A1 (ja) * | 2004-01-30 | 2005-08-11 | Sumitomo Chemical Company, Limited | 脂肪量増加抑制能力の検定方法 |
US20050276804A1 (en) * | 2004-06-14 | 2005-12-15 | Wisconsin Alumni Research Foundation | Method for preventing or treating cardiac hypertrophy |
WO2007137239A2 (en) * | 2006-05-19 | 2007-11-29 | The Scripps Research Institute | Treatment of protein misfolding |
EP2052088A2 (en) * | 2006-08-02 | 2009-04-29 | Genizon Biosciences | Genemap of the human genes associated with psoriasis |
CN101838689A (zh) * | 2010-01-14 | 2010-09-22 | 广州市妇女儿童医疗中心 | 一种快速诊断染色体数目异常的多重qf-pcr str检测体系 |
CN110327363A (zh) * | 2019-06-11 | 2019-10-15 | 华中科技大学同济医学院附属同济医院 | 基于hsa-miR-320a的防治糖尿病的药物及其筛选方法和制备方法 |
Non-Patent Citations (2)
Title |
---|
沈才齐等: "人脐带间充质干细胞治疗糖尿病创面效果及其在体内存活、定植研究", 徐州医科大学学报, vol. 42, no. 01, pages 25 - 29 * |
魏立民: "胆囊收缩素与糖尿病", 国外医学(内分泌学分册), vol. 23, no. 06, pages 419 - 421 * |
Also Published As
Publication number | Publication date |
---|---|
CN116407636B (zh) | 2023-10-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Li et al. | M2 microglial small extracellular vesicles reduce glial scar formation via the miR-124/STAT3 pathway after ischemic stroke in mice | |
Yang et al. | MiR-126 overexpression inhibits high glucose-induced migration and tube formation of rhesus macaque choroid-retinal endothelial cells by obstructing VEGFA and PIK3R2 | |
Liu et al. | MicroRNA-140 inhibits skeletal muscle glycolysis and atrophy in endotoxin-induced sepsis in mice via the WNT signaling pathway | |
CN110656111A (zh) | Pno1抑制剂在制备食管癌治疗药物中的用途 | |
Chen et al. | Cholesterol modification of SDF-1-specific siRNA enables therapeutic targeting of angiogenesis through Akt pathway inhibition | |
CN110592222B (zh) | Triml1作为肝癌的分子标记物的应用 | |
CN109432119B (zh) | 一种circRNA抑制血管新生领域的应用 | |
Wang et al. | Decreased expression of microRNA‑145 promotes the biological functions of fibroblasts in hypertrophic scar tissues by upregulating the expression of transcription factor SOX‑9 | |
CN112933112B (zh) | 氧化石墨烯或其调控分子在制备促进糖尿病创面修复的药物中的应用 | |
CN110917357B (zh) | 人gsdmb基因的用途及相关产品 | |
CN116407636B (zh) | Lnc-CCKAR-5在制备促进糖尿病创面修复的药物中的应用 | |
CN111110691A (zh) | 人参皂苷Rb2在制备预防和/或治疗动脉粥样硬化药物中的应用 | |
CN110791566A (zh) | 人shcbp1基因的用途及相关产品 | |
CN103656681A (zh) | 一种用于治疗脓毒症急性肺损伤的小核酸药物 | |
CN112063710A (zh) | 长链非编码rna的诊断和治疗用途 | |
CN115337322B (zh) | 一种rna在制备治疗肺纤维化相关疾病的产品中的应用 | |
CN103667430A (zh) | 一种八聚核苷酸结合蛋白表达基因的用途及其相关药物 | |
CN112280859B (zh) | 一种乳腺癌标志物及应用 | |
JP6363737B2 (ja) | 瘢痕形成を軽減する医薬組成物及び方法 | |
CN103301474B (zh) | 人rnf40基因的用途及其相关药物 | |
CN114177298B (zh) | Adar1作为治疗肺动脉高压疾病药物的应用 | |
CN117398464B (zh) | circRERE的抑制剂在制备缺血性心脏病治疗药物中的应用 | |
CN103667423B (zh) | 人ifitm3基因的用途及其相关药物 | |
CN110882390B (zh) | 人lsm5基因的用途及相关产品 | |
CN107184984A (zh) | Rpl10的抑制剂在制备治疗卵巢癌的药物中的应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |